Thalidomide decreases intrahepatic resistance in cirrhotic rats

Biochemical and Biophysical Research Communications

Volumn 380, Issue 3, 2009, Pages 666-672

  Yang, Ying Ying ^a,b   Huang, Yi Tsau ^b   Lin, Han Chieh ^a,b   Lee, Fa Yauh ^a,b   Lee, Kuei Chuan ^a,b   Chau, Ga Yang ^a,b   Loong, Che Chuan ^a,b   Lai, Chiung Ru ^a,b   Lee, Shou Dong ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Cirrhosis; Perfusion; Thalidomide; Tumor necrosis factor alpha

Indexed keywords

CD45 ANTIGEN; HYDROXYPROLINE; THALIDOMIDE; THROMBOXANE SYNTHASE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BILE DUCT; CONTROLLED STUDY; DRUG EFFECT; LIVER CIRRHOSIS; LIVER FUNCTION; LIVER PERFUSION; MALE; MICROCIRCULATION; NONHUMAN; PORTAL VEIN BLOOD FLOW; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

ANIMALS; ANTIGENS, CD45; CELL MOVEMENT; IMMUNOSUPPRESSIVE AGENTS; LEUKOCYTES; LIPOPOLYSACCHARIDES; LIVER; LIVER CIRRHOSIS, BILIARY; MALE; MICROCIRCULATION; PORTAL VEIN; RATS; RATS, SPRAGUE-DAWLEY; THALIDOMIDE; THROMBOXANE-A SYNTHASE; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR RESISTANCE; VENOUS PRESSURE;

RATTUS;

EID: 60549102643     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2009.01.160     Document Type: Article

References (30)

1. Cirera I., Bauer T., Navasa M., Vila J., Grande L., Taura P., Fuster J., Garcia-Valdecasas J.C., Lacy A., Sauez M.J., Rimola A., and Rodes J. Bacterial translocation of enteric organism in patients with cirrhosis. J. Hepatol. 34 (2001) 32-37
2. Szabo G., Romics Jr. L., and Frendl G. Liver in sepsis and systemic inflammatory response syndrome. Clin. Liver Dis. 6 (2002) 1045-1066
3. Goulis J., Patch D., and Burroughs A.K. Bacterial infection in the pathogenesis of variceal bleeding. Lancet 353 (1999) 139-142
4. 2. J. Hepatol. 47 (2007) 228-238
5. Tomita K., Tamiya G., Ando S., Ohsumi K., Chiyo T., Mizutani A., Kitamura N., Toda K., Kaneko T., Horie Y., Han J.Y., Kato S., Shimoda M., Oike Y., Tomizawa M., Makino S., Ohkura T., Saito H., Kumagai N., Nagata H., Ishii H., and Hibi T. Tumour necrosis factor alpha signalling through activation of Kupffer cells plays an essential role in liver fibrosis of non-alcoholic steatohepatitis in mice. Gut 55 (2006) 415-424
6. Bauer I., Bauer M., Pannen B.H., Leinwand M.J., Zhang J.X., and Clemens M.G. Chronic ethanol consumption exacerbates liver injury following hemorrhagic shock: role of sinusoidal perfusion failure. Shock 4 (1995) 324-331
7. Reynaert H., Urbain D., and Geerts A. Regulation of sinusoidal perfusion in portal hypertension. Anat. Rec. 291 (2008) 693-698
8. Vollmar B., Siegmund S., and Menger M.D. An intravital fluorescence microscopic study of hepatic microvascular and cellular derangements in developing fibrosis in rats. Hepatology 27 (1998) 1544-1553
9. Isayama F., Hines I.N., Kremer M., Milton R.J., Byrd C.L., Perry A.W., McKim S.E., Parsons C., Rippe R.A., and Wheeler M.D. LPS signaling enhances hepatic fibrogenesis caused by experimental cholestasis in mice. Am. J. Physiol. Gastrointest. Liver Physiol. 290 (2006) G1318-G1328
10. Koeppel T.A., Trauner M., Bass J.C., Thies J.C., Schlosser S.F., Post S., Gebhard M.M., Hertarth C., Boyer J.C., and Otto G. Extrahepatic biliary obstruction impairs microvascular perfusion and increases leukocyte adhesion in rat liver. Hepatology 26 (1997) 1085-1091
11. Gujral J.S., Farhood A., Bajt M.L., and Jaeshke H. Neutrophils aggravate liver injury during obstructive cholestasis in bile duct-ligated mice. Hepatology 38 (2003) 355-363
12. Jaeschke H., and Smith C.W. Mechanisms of neutrophil-induced parenchymal cell injury. J. Leukocyte Biol. 61 (1997) 647-653
13. Saito J.M., and Maher J.J. Bile duct ligation in rats induces biliary expression of cytokine-induced neutrophil chemottractant. Gastroenterology 118 (2000) 1157-1168
14. Enomoto N., Takei Y., Hirose M., Ikejima K., Miwa H., Kitamura T., and Sato N. Thalidomide prevents alcoholic liver injury in rats through suppression of kupffer cell sensitization and TNF-α production. Gastroenterology 123 (2002) 291-300
15. Matthews S.J., and McCoy C. Thalidomide: a review of approved and investigational uses. Clin. Ther. 25 (2003) 365-376
16. Austin A.S., Mahida Y.R., Clarke D., Ryder S.D., and Freeman J.G. A pilot study to investigate the use of oxpentifylline (pentoxifylline) and thalidomide in portal hypertension secondary to alcoholic cirrhosis. Aliment. Pharmacol. Ther. 19 (2005) 79-88
17. Lopez-Talavera J.C., Cadelina G., Olchowski J., Merrill W., and Groszmann R.J. Thalidomide inhibits tumor necrosis factor-α, decrease nitric oxide synthesis and ameliorates the hyperdynamic circulatory syndrome in portal-hypertensive rats. Hepatology 23 (1996) 1616-1621
18. Yeh T.S., Ho Y.P., Huang S.F., Yeh J.N., Jan Y.Y., and Chen M.F. Thalidomide salvages lethal hepatic necroinflammation and accelerates recovery from cirrhosis in rats. J. Hepatol. 41 (2004) 606-612
19. Paul S.C., Lv P., Xiao Y.J., Liu S.Q., and Luo H.S. Thalidomide in rat liver cirrhosis: blockade of tumor necrosis factor-alpha via inhibition of degradation of an inhibitor of nuclear factor-kappaB. Pathobiology 73 (2006) 82-92
20. Lv P., Paul S.C., Xiao Y., Liu S., and Luo H. Effects of thalidomide on the expression of adhesion molecules in rat liver cirrhosis. Mediators Inflamm. 2006 4 (2006) 93253
21. Lv P., Luo H.S., Zhou X.P., Xiao Y.J., Paul S.C., Si X.M., and Zhou Y.H. Reversal effect of thalidomide on established hepatic cirrhosis in rats via inhibition of nuclear factor-kappaB/inhibor of nuclear nuclear factor-kappaB pathway. Arch. Med. Res. 38 (2007) 15-27
22. Chong L.W., Hsu Y.C., Yang K.C., and Huang Y.T. Anti-fibrotic effects of thalidomide in hepatic stellate cells and dimethylnitrosamine-intoxicated rats. J. Biochem. Sci. 13 (2006) 403-418
23. Fernandez-Martinez E., Marales-Rios M.S., Perez-Alvarez V., and Muriel P. Effect of thalidomide and 3-phthalimido-3-(3, 4-dimethoxyphenyl)-propanamide on bile duct obstruction-induced cirrhosis in the rat. Drug Dev. Res. 54 (2001) 209-218
24. Lin H.C., Huang Y.T., Wu H.L., Lee W.C., Hou M.C., Lee F.Y., Chang F.Y., and Lee S.D. Effect of sustained release lanreotide on hemodynamics in rats with portal vein stenosis. J. Hepatol. 31 (1999) 482-488
25. Yang Y.Y., Lin H.C., Huang Y.T., Lee T.Y., Hou M.C., Wang Y.W., Lee F.Y., and Lee S.D. Roles of anandamide in the hepatic microcirculation in cirrhotic rats. Am. J. Physiol. Gastrointest. Liver Physiol. 290 (2006) G328-G334
26. Ueki M., Koda M., Yamamoto S., Matsunaga Y., and Murawaki Y. Preventive and therapeutic effects of angiotensin II type 1 receptor blocker on hepatic fibrosis induced by bile duct ligation in rats. J. Gastroenterol. 41 (2006) 996-1004
27. Green R.M., Bier M., and Gollan J.L. Regulation of hepatic bile salt transporters by endotoxin and inflammatory cytokines in rodents. Gastroenterology 111 (1996) 193-198
28. Lee W.Y., and Kubes P. Leukocyte adhesion in the liver: distinct adhesion paradigm from other organs. J. Hepatol. 48 (2008) 504-512
29. Geerts A.M., Cheung K.J., Vlierberghe H.V., Vriese A.S.D., Mortier S., Vanheule E., Lameire N., Vos M.D., and Colle I. Decreased leukocyte recruitment in the mesenteric microcirculation of rats with cirrhosis is partially restored by treatment with peginterferon: an in vivo study. J. Hepatol. 46 (2007) 804-815
30. 4-treated rats. J. Hepatol. 33 (2000) 555-563